October 11, 2021
20211011 Notice of Annual General MeetingProxy Form
-
-
September 23, 202120210923 AnteoTech Signs Romanian Distribution Agreement for EuGeni
-
September 23, 202120210923 InvestorStream Interview Presentation
-
September 23, 202120210923 Therapeutic Goods Administration Registration Submitted
-
-
September 16, 2021AnteoTech Ltd is pleased to advise that it has signed a Distribution Agreement (Agreement) with Ramma Dental SA (Ramma Dental) for the distribution of the EuGeni Reader platform and SARS-CoV-2 Antigen...
-
September 6, 2021AnteoTech Ltd is pleased to advise that it has signed a Distribution Agreement (Agreement) with Pera Medikal Anonim Sirketi (Pera Medikal) for the distribution of the EuGeni Reader platform and SARS-C...
-
September 1, 202120210901 ADO positions Board for growth establishes Advisory Boards
-
-
August 6, 202120210806 AnteoTech Signs EuGeni Philippines Distribution Agreement
-
-
August 3, 202120210803 Application for quotation of securities - ADO
-
-
August 2, 202120200802 AnteoTech renews and extends CEO contract
-
August 2, 202120210802 Annual executive and staff review process
-
August 2, 202120210802 Application for quotation of securities - ADO
-
August 2, 202120210802 Notification of cessation of securities - ADO
-
August 2, 202120210802 Notification regarding unquoted securities - ADO
-
-
-
-
July 27, 2021AnteoTech Ltd is pleased to advise that it has signed a Distribution Agreement (Agreement) with Apacor Limited (Apacor) for the distribution of the EuGeni Reader platform and SARS-CoV-2 Antigen Rapid ...
-
July 19, 2021AnteoTech Ltd is pleased to advise that it has signed a Distribution Agreement (Agreement) with Abacus dx Pty Ltd (Abacus) for the distribution of the EuGeni Reader platform and SARS-CoV-2 Antigen Rap...
-
July 18, 2021AnteoTech Ltd (ASX: ADO) (“AnteoTech” or “the Company”) is pleased to announce the signing of a Distribution Agreement (Agreement) with Biomed Global Sdn. Bhd (Biomed) and its subsidiaries for the dis...
-
May 23, 2021AnteoTech Ltd is pleased to provide an overview of the lateral flow rapid test manufacturing strategy developed to meet anticipated demand for the range of tests being developed for the EuGeni platfor...
-
May 20, 2021AnteoTech had received applications totalling $37.1 million by the close of the SPP on 18 May 2021. Given the overwhelming support, the Board has exercised its discretion to increase the SPP from $4 m...
-
May 16, 2021AnteoTech Ltd is pleased to announce that it has finalised and signed a manufacturing contract for its COVID-19 Antigen Rapid Test (ART) with Zaragoza (Spain) based contract manufacturer Operon. 20...
-
-
-
-
-
-
-
-
-
April 28, 2021202010428 AnteoTech secures funding to support launch and pipeline
-
April 25, 2021AnteoTech Ltd requests an immediate trading halt in respect of its quoted shares and options.20210426 Trading Halt
-
April 25, 2021AnteoTech Ltd is pleased to report that evaluation work conducted by AnteoTech’s Collaborators, focusing on the application of AnteoX, has proven very successful. The collaborative work and results ha...
-
April 22, 2021The Board and Chief Executive Officer of Brisbane-based biotech company, AnteoTech Ltd invite shareholders and investors to join the live stream Webinar of the media and public launch of the EuGeni Re...
-
April 11, 2021AnteoTech Ltd is pleased to advise that it has received Conformitè Europëenne (CE) Mark registration for its EuGeni Reader and the in vitro rapid diagnostic test for the detection of SARS-CoV-2 nucleo...
-
April 8, 2021AnteoTech is pleased to advise that it has executed a Project Participation Agreement with the Future Battery Industries CRC (FBICRC), for collaboration in “The Super Anode Project”. 20210409 Anteo...
-
March 31, 2021AnteoTech Ltd is pleased to announce the appointment of Ms Gail Jukes as Chief Financial Officer (CFO) effective 1st July 2021. 20210331 AnteoTech appoints Chief Financial Officer
-
March 25, 2021AnteoTech Ltd is pleased to provide shareholders and the market with the updated “Company Presentation”. 20210325 Updated Company Presentation
-
March 22, 2021AnteoTech Ltd is pleased to provide a copy of the presentation by CEO Derek Thomson for the InvestorStream interview. The interview is available at: https://www.investorstream.com.au/anteotech-relea...
-
March 21, 2021Brisbane based nanotechnology company AnteoTech Ltd is pleased to report the outcome of the COVID-19 ART clinical study conducted and reviewed by the Victorian Infectious Diseases Reference Laboratory...
-
-
-
February 26, 2021Half-Year Report For the half-year ended 31 December 2020 This half-year report is provided by AnteoTech Ltd to the Australian Stock Exchange (ASX) under ASX Listing Rule 4.2A.3. This information ...
-
February 3, 2021Brisbane based nanotechnology company AnteoTech Ltd notes our customer Ellume has made an announcement of an agreement with the U.S. Department of Defense (DOD) for its Emergency Use Authorization (EU...
-
January 29, 2021Activities for the Quarter in the Life Sciences Division focused on the development of the COVID-191 Antigen Rapid Test (ART), including clinical studies and commercial arrangement for manufacturing. ...
-
-
January 20, 2021Brisbane based AnteoTech Ltd is pleased to announce that it has been awarded up to $1.4 million towards the further development and commercialisation of its COVID-19 Antigen Rapid Test, under the Quee...
-
December 23, 2020AnteoTech Ltd is pleased to provide a brief update on the COVID-19 Antigen Rapid Test (ART) development program. 20201224 AnteoTech Progresses COVID-19 Test Toward Market Launch
-
-
-
December 9, 2020AnteoTech Ltd is pleased to advise that it has now received the full $3.9 million from the exercise of all 195,187,019 listed options (ADOO) which had an expiry date of 6 December 2020 and were exerc...
-
-
-
-
November 26, 2020AnteoTech Ltd is pleased to advise that it has received a cash refund of $1,195,634 under the Federal Government’s Research & Development Tax Incentive Scheme. 20202227 $1.19 million R&D Tax In...
-
November 25, 2020AnteoTech Ltd is pleased to announce that all development processes and internal testing procedures for the high sensitivity COVID-19 Antigen Rapid Test (ART) are complete and the Company has declare...
-
November 23, 202020201123 Change of Director's Interest Notice
-
-
November 16, 202020201116 Change of Director's Interest Notice x4
-
-
-
-
-
-
-
-
-
-
-
-
-
October 21, 202020201021 Study Confirms Targeted Sensitivity of COVID-19 Test
-
-
-
-
October 9, 202020201009 Notice of Annual General MeetingProxy Form
-
-
-
-
September 10, 202020200910 AnteoTech Achieve ISO-13485 Certification
-
September 9, 202020200909 AnteoTech COVID-19 Antigen Test Progress Update
-
-
-
-
-
July 17, 2020AnteoTech develops proof of concept COVID-19/Flu A&B multiplex test platform Tests leverage AnteoBind activated Europium particle technology designed for high sensitivity COVID-19 antig...
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
November 28, 2019IMRA Contrcat Additional Information 28:11:19
-
-
November 18, 2019AnteoTech signs commercial contract 18:11:19
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-